block the function of HER2, which causes fast growing, aggressive
breast cancer tumours. Herceptin delivers high cure rates for women
with HER2 positive early breast cancer and extends survival across all
stages of HER2 positive breast cancer by activating the immune system
and suppressing HER2. Herceptin is considered the foundation of care in
women with HER2-positive breast cancer and is recommended in treatment
guidelines throughout the world.
-- Colorectal cancer is the most common cancer in developed countries(4)
and the second most common cause of death from cancer across all cancer
types in men and women across Europe.(5)
-- Avastin acts by blocking VEGF, the key mediator of tumor angiogenesis,
offering patients a better chance of significantly improved survival.
Avastin is the first anti-angiogenic inhibitor to increase survival in
first and second line treatment and to provide significant improvements
in the time that patients can live without their disease advancing.
The 2008 ASCO Annual Meeting takes place from May 31 to June 3, McCormick Place, Chicago, Illinois, USA. Full details can be found at http://www.asco.org .
If you or your media colleagues are interested in attending the Roche
Media Event during ASCO on 30th May, where the data outlined in brief above
will be presented, please contact Anne Cameron (see details below).
1. Wilking N and Jonsson B. A Pan-European comparison regarding patient
access to cancer drugs. Karolinska Institute in collaboration with
Stockholm School of Economics, Stockholm, Sweden, 2005
2. World Health Organisation (WHO) 2003.
Copyright©2008 PR Newswire.
All rights reserved